From Laboratory to Spin-Off: The Three Publications That Secured €1.2 Million in Grant Funding

In the autumn of 2023, a research group at a mid-sized European technical university had a problem that is simultaneously very common and almost never discussed in the literature on university commercialisation: their technology worked, their market was real, their team was capable, and they had no idea how to prove any of this to the people who controlled the money.

The lead researcher — a materials scientist twelve years into her academic career — had published nine papers in the preceding five years. Three of them were in high-quality journals. The rest were solid contributions to the field that had each generated perhaps forty citations. None had been cited by a non-academic source. None had been read, as far as she could tell, by anyone who worked in industry.

The technology she had developed was a functional coating for medical implant surfaces that dramatically reduced bacterial adhesion without the use of conventional antibiotics. The clinical problem it addressed — device-associated infections, which affect approximately 2 million patients annually in Europe and account for roughly 30% of all hospital-acquired infections — was genuine, large, and inadequately solved by existing approaches.

By the end of 2024, a spinout company had been incorporated, a €1.2 million grant had been awarded by a national innovation agency in partnership with a European funding programme, and a co-investor from the medtech sector had committed to a seed round conditional on the grant. The journey between those two points was not primarily a story about the technology. It was a story about three publications and the decisions made around them.

The Audit: Understanding What Was Missing

The first thing the research group did — with external assistance — was conduct an honest assessment of their existing publication record against the evidence base that grant evaluators and potential co-investors would need to see.

The assessment identified three gaps:

1. The market problem was not quantified in their own published work

   The nine papers described the technology and its performance in controlled laboratory conditions. None established, with peer-reviewed evidence, the scale of the clinical problem the technology was designed to solve, or the inadequacy of existing solutions. The team knew the problem was large and serious — but that knowledge lived in their own heads and in sources they had cited in grant applications without having contributed to the evidence base themselves.

2. The performance comparison was against academic benchmarks rather than clinical ones

   The published results showed that the coating outperformed previous academic approaches by substantial margins. They did not show how it compared to the commercially available implant coatings currently used in clinical practice — which was the comparison that any clinical investor or hospital procurement committee would need to see.

3. The clinical context was entirely absent

   Every publication had been produced in collaboration with other materials scientists. No clinician had been involved in any publication. The team had never co-authored with a surgeon, an infection control specialist, or a clinical microbiologist — which meant the clinical relevance of their technology had never been externally evaluated by anyone with clinical expertise.

These three gaps were not problems with the science. They were problems with the evidence architecture around the science — specifically, the evidence architecture that grant evaluators and medtech investors are trained to look for.

The plan that emerged from this audit was simple: close all three gaps with peer-reviewed publications before the grant application deadline, fifteen months away.

The Systematic Review — Establishing the Problem

The first decision was the most counterintuitive for a materials science research group: to spend three months writing a systematic review that contained no original experimental data from their own laboratory.

The systematic review synthesised the existing clinical literature on device-associated infection: the incidence data, the cost data, the mortality and morbidity statistics, the current prevention strategies and their documented failure rates, and the performance targets that would need to be met by any solution aspiring to clinical adoption. It was co-authored with a clinical microbiologist at a teaching hospital who had spent fifteen years studying device-associated infection and who had been collaborating informally with the materials science group for two years without ever appearing on a publication.

The paper was submitted to a journal at the intersection of biomaterials and clinical microbiology — a venue chosen deliberately because it was read by both communities and indexed in both the materials science and clinical databases that grant evaluators would search.

The systematic review did several things simultaneously. It established the scale of the problem in peer-reviewed form, with the research group's names on it. It brought a credentialled clinical co-author onto the team's publication record for the first time. It positioned the research group as people who understood the clinical context of their technology — not just the materials science. And it created a citable peer-reviewed evidence base for the market validation claims that would appear in every grant application they submitted.

The paper was accepted seven months after submission and published three months later. It has been cited forty-two times in its first year — more than any previous publication from the laboratory.

The Clinical Benchmark Paper — Establishing the Performance Gap

The second publication addressed Gap 2: the absence of a clinical performance comparison. This paper required the most significant methodological investment of the three, because it involved running a set of standardised tests — borrowed from the clinical microbiology literature rather than the materials science literature — that the research group had not previously used in their published work.

The paper compared the bacterial adhesion performance of the group's coating against three commercially available implant coatings representing the current clinical standard in their target application area. The tests were conducted using clinical bacterial strains — isolated from actual device-associated infection cases, provided by the clinical co-author's institution — rather than the reference laboratory strains that the materials science literature typically used.

The results were stark. The three commercial coatings reduced bacterial adhesion by between 23% and 47% compared to uncoated controls, under the clinical test conditions. The research group's coating reduced it by 91%.

This number — 91% versus 23-47% — was the commercial heart of the eventual spinout. But it had never appeared in a peer-reviewed publication in a form that compared the coating directly against clinical competitors under clinically relevant conditions. The first eight papers had been evaluated against academic reference points. This paper was the first to answer the question that every clinical investor would ask: compared to what is currently used in hospitals, how much better is this?

The paper was submitted to a clinical biomaterials journal with a significant clinical readership and accepted within five months, with relatively minor revisions. The speed of review was itself a signal: the result was clear, the clinical comparison was well-designed, and the reviewers — two of whom, based on their comments, appeared to be clinicians rather than materials scientists — found the result significant.

The Clinical Pilot Data — Establishing Translational Credibility

The third paper was the most important and the most difficult to produce. It required not just a new experimental design but a new kind of institutional relationship: an approved collaboration with a hospital ethics committee, a surgeon, and an infection control team, to generate preliminary data on the coating's performance in a model that approximated clinical conditions more closely than anything a laboratory could produce.

The paper described a 60-sample ex vivo study using tissue from surgical waste — material that was ethically approved for research use — to evaluate the coating's performance on surfaces exposed to the physical and chemical environment of a surgical site. It was not a clinical trial. It was not patient data. But it was the first peer-reviewed evidence that the coating performed in conditions that moved beyond the highly controlled laboratory environment of the previous eight publications.

The clinical co-author was now the second author, and two additional co-authors — the surgeon who had provided the tissue access and the infection control specialist who had designed the bacterial challenge protocol — appeared on the paper for the first time. The author list of this paper was, in itself, evidence: it showed that the team could navigate a clinical institution's ethics process, work with practising clinicians, and produce a result that those clinicians were willing to put their names on.

This paper took eleven months from design to acceptance. It was the last piece of the evidence architecture to fall into place, arriving in its final accepted form six weeks before the grant application deadline.

The Grant Application: How the Three Papers Functioned

The grant application was for a national innovation programme with co-funding from a European framework. The total amount awarded was €1.2 million — sufficient to fund the spinout's operations for eighteen months, complete the validation studies required for a regulatory submission, and attract a co-investor.

In the application, the three papers functioned as follows:

The systematic review was cited in the market analysis section as the primary evidence base for the clinical problem statement. Every claim about incidence, cost, and inadequacy of current solutions referenced the systematic review rather than the founding team's assertions — because the systematic review was peer-reviewed, independently cited, and could be verified by any evaluator with database access. The grant evaluators did not need to take the founding team's word for the market problem. They could read the paper.

The clinical benchmark paper was cited in the technology validation section as the evidence for the core performance claim. The key figure — 91% bacterial adhesion reduction versus 23-47% for commercial competitors — appeared in the application with the full citation, accessible to any evaluator who wanted to verify the methodology or the statistical analysis. The evaluators' technical reviewer specifically noted that the comparison against commercial standards was a distinguishing feature of the application.

The ex vivo pilot paper was cited in the translational credibility section as evidence that the technology had been evaluated beyond purely laboratory conditions, and that the clinical partnership necessary for regulatory-pathway navigation was already operational rather than aspirational. The clinical co-authors' institutional affiliations were explicitly noted as evidence of the team's access to the clinical environment that the development programme would require.

What This Case Teaches

The technology in this case study existed before the three strategic publications. The team's capability existed before the three publications. The clinical relationship existed — informally — before the three publications. What the publications did was make all of these things legible in a form that grant evaluators, and subsequently co-investors, could evaluate without having to take the founding team's word for anything.

This is the insight that most researcher-founders miss: the publication strategy is not separate from the commercialisation strategy. It is the commercialisation strategy — the mechanism by which the maturity of the science is made legible to the people who will fund its translation.

Four Decisions That Made the Difference

None of these decisions required more resources than the team already had. They required a different framing of what the publications were for.